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Abstract 14 
New Psychoactive Substances (NPS) are compounds that produce similar effects to those induced by 15 
illicit drugs (ID), such as cocaine, cannabis and amphetamines, but are not strictly regulated by 16 
international conventions. The consumption of NPS is a growing public health problem in many 17 
communities. However, there is little knowledge regarding the extent and actual use of these new 18 
substances. Monitoring NPS use is arduous and, therefore, different sources of information need to 19 
be used to get more insight of the prevalence and diffusion of NPS use. Analysis of pooled urine (PU) 20 
and wastewater (WW) shows strong potential, giving a different and complementary light on this 21 
issue, although presents some limitations and challenges that must be taken into account. Liquid 22 
Chromatography coupled to High Resolution Mass Spectrometry (LC-HRMS) is one of the most 23 
powerful approaches for screening a large number of NPS because of the accurate-mass full-spectrum 24 
acquisition measurements. By using a comprehensive and updated NPS database, LC-HRMS is flexible 25 
enough to confront the ever-changing NPS market.  In this “current opinion”, we give our point of view 26 
on the usefulness of PU and WW analysis, and on the potential application of wastewater-based 27 
epidemiology as source of information for NPS use, explaining the main bottlenecks and future 28 
perspectives in this emerging research field. 29 
 30 
Keywords New Psychoactive Substances, pooled urine, urban wastewater, wastewater-based 31 
epidemiology, mass spectrometry   32 
Introduction 33 
New Psychoactive Substances (NPS) can be defined as substances that produce similar effects to those 34 
induced by illicit drugs (ID) such as cocaine, cannabis and amphetamines, but are not strictly regulated 35 
by international conventions [1]. Although many NPS are synthesized introducing only minor 36 
modifications to the chemical structures of controlled substances, the term ‘new’ does not directly 37 
refer to ‘newly developed’ chemicals, but to ‘newly misused’ substances [2]. The NPS market is, 38 
therefore, very dynamic creating, quickly, new alternative substitutes. Hence, the  Early Warning 39 
System (EWS) of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) reported 40 
more than 670 different NPS between 2005 and 2017 [3]. NPS can be classified in different categories 41 
depending on their structural back-bone. Cathinones and synthetic cannabinoids are most often 42 
reported, but also benzodiazepines, arylcyclohexylamines, phenethylamines and synthetic opioids 43 
were found (Figure 1) [3]. These new drugs have become easily available to the general public mainly 44 
through e-commerce, and are considered a growing problem in many communities since they are 45 
responsible for numerous fatal intoxications [4–6]. Although several countries have suffered the 46 
emergence of NPS i.e. use and harms, not all governments have been able to act upon all of them in 47 
an effective way in terms of penalizing its supply and use [7,8].  48 
Understanding the extent and actual use of NPS is important for healthcare professionals and 49 
toxicologists to assess the risks associated, but also for policy makers to help orient prevention and 50 
define law enforcement activities. Different sources of information, such as general population 51 
surveys [9–11], EWS [3], internet [12], seizure data [13–16]  and the analysis of biological samples 52 
(urine of users from hospital emergency rooms, post-mortem fluids...) [17–20], can be consulted to 53 
get insight of the prevalence and diffusion of NPS use. 54 
 A recent approach that shed a different light on this issue is the analysis of pooled urine (PU) and 55 
urban wastewater (WW) samples. PU and WW analysis can provide anonymized, but comprehensive 56 
and objective information, on community-wide use of NPS [21–24]. The wastewater-based 57 
epidemiology (WBE) approach relies on the fact that traces of almost everything humans consume are 58 
excreted, unaltered or as metabolites, via urine or feces [25]. Thus, the determination of appropriate 59 
urinary excretion products (biomarkers) and subsequent concentration data in WW can be used to 60 
estimate illicit and licit drug use by a population [25,26]. The Sewage analysis CORe group Europe 61 
(SCORE) has promoted and coordinated WBE campaigns for the worldwide monitoring of ID 62 
consumption since 2011 [27–29] reporting the results to the EMCDDA, who considers WBE as a 63 
complementary source of information to the conventional indicators on drug use. In addition, the 64 
Australian Criminal Intelligence Commission (as part of their drug monitoring program: 65 
https://www.acic.gov.au/publications/intelligence-products/national-wastewater-drug-monitoring-66 
program-report [30]), as well as New Zealand and China have set up strategies to implement such 67 
studies in their countries. For the proper application of WBE, however, several key aspects such as the 68 
selection of suitable and unique biomarkers and excretion rates need to be taken into account in order 69 
to obtain population-normalized quantitative data i.e. information on amounts consumed [31–34]. 70 
WBE has been successfully applied to the monitoring of tobacco [35,36], alcohol [37] and ID use 71 
[27,28,33,38], and has the potential to detect and discover newly consumed NPS [25,26,39,40].  72 
In this review, we give our viewpoint on the monitoring of NPS in PU and WW, and the potential 73 
application of WBE in this field, with special emphasis on challenges and limitations. Finally, future 74 
perspectives are briefly presented. The analysis of PU has been included in this paper due to the very 75 
few studies available of NPS in WW (in comparison to conventional ID) and the challenges to obtain 76 
information of NPS use from WW, as explained later in the manuscript. In addition, searching for NPS 77 
in PU can provide useful and complementary information on this topic. 78 
 79 
Analytical challenges for monitoring NPS 80 
The ever-changing nature of NPS poses a challenge for analytical forensic laboratories. The NPS market 81 
is very dynamic and the rapid introduction of new substances makes it highly difficult to keep the 82 
analytical methodologies up to date. The detection, identification and quantification of NPS is time-83 
consuming, complex and expensive. However, identifying the new substances that are appearing in 84 
the market is the first necessary step in assessing the risks associated with these substances and in 85 
controlling potentially dangerous new drugs. Under these circumstances, the analysis of commercially 86 
available products (sometimes known as ‘legal highs’) provides updated information of the 87 
compounds possibly consumed.  A combination of several techniques, such as NMR, HRMS, GC-MS, 88 
X-ray crystallography, FTIR, ultraviolet and circular dichroism, is often needed for a full 89 
characterization and true confirmation of the identity of unknown new drugs [41–46]. 90 
The continuous appearance of new substances joined to the limited availability of reference standards 91 
and difficulties to purchase them make the development of quantitative target methods somehow a 92 
limited approach and non-affordable task when monitoring hundreds of changing NPS. Therefore, 93 
there is an increasing interest in developing qualitative screening methodologies able to detect and 94 
identify a large number of compounds. The hyphenation of liquid chromatography (LC) with high 95 
resolution mass spectrometry (HRMS) is one of the most powerful approaches to this aim [47–49]. LC-96 
HRMS appears as the technique of choice due to the polar character of most NPS, especially of 97 
metabolites, and the useful information contained in accurate-mass full-spectrum acquisition data.  98 
The main reason for the shift toward qualitative, suspect screening methodologies based on LC-HRMS, 99 
is that there is, in principle, no need of reference standards for tentative identifications and the list of 100 
compounds that can be searched is only limited by the suspect screening database [39,47,48,50,51]. 101 
To help in the identification of NPS, a new web-based database (NPS Data Hub) has been developed 102 
with the aim to elicit data from the forensic laboratories to facilitate identification of unknown 103 
substances [52]. In this way, the time for valuable data to be accessible to analytical laboratories for 104 
identification of newly emerging compounds is notably reduced. Analytical data of any type can be 105 
added for a given compound, but the mostly applied techniques are NMR, (HR)MS and IR/Raman. The 106 
combination of a compound database and HRMS spectral library represents a useful tool for the 107 
identification of NPS in forensic HRMS-based screening applications [53]. 108 
If the identification of NPS in commercially available products (herbal blends, powder, pilots, crystals, 109 
etc.) is complex, the detection and identification of NPS residues in urine samples is even more 110 
challenging. Unfortunately, most of the techniques mentioned above are not useful in this type of 111 
analysis due to the low analyte concentrations in the samples, and the complex nature of the urine 112 
matrix with endogenous components being at concentrations much higher than the NPS potentially 113 
consumed. In addition, the low rate of positive findings when analyzing individual urine samples 114 
complicates even more the monitoring of NPS. To this aim, the analysis of pooled urine samples from 115 
hundreds (or thousands) of individuals at specific settings with higher probability of NPS consumption 116 
is preferred. Nightlife areas, music festivals or local festivities are strategic locations for the collection 117 
of PU samples from the inner container of pissoirs or portable toilets. The likelihood of having NPS 118 
consumers among all PU contributors increases the rate of success in identifying NPS consumed.  119 
Additional difficulties appear in the investigation of NPS in wastewater, mainly because of the 120 
extremely low concentrations of NPS due to the lower consumption in comparison with popular, 121 
conventional ID, and to the high dilution factor in WW. The main drawback of LC-HRMS screening of 122 
NPS in PU or WW comes from its lower sensitivity compared to target quantitative methods (e.g. by 123 
LC-MS/MS QqQ), an aspect that is crucial in this field. In addition, strong ionization suppression 124 
commonly occurs on the analyte signal in these complex matrices. For this reason, the target 125 
quantitative methods (e.g. LC-MS/MS with triple quadrupole (QqQ)) are still valuable, although they 126 
are restricted to the limited target list of compounds included in the scope of the method, with the 127 
corresponding reference standards being required for method optimization, data acquisition and 128 
quantification [23,24,49,54–57].  129 
Another relevant issue is NPS metabolism, which plays a key role for the selection of appropriate 130 
biomarkers (parent compound or metabolites) for monitoring NPS in PU or WW. Due to the general 131 
lack of information on metabolic pathways for many NPS, there is a great interest in the scientific 132 
community to perform metabolic studies to identify compounds proposed as target compounds in 133 
urine or in WW [58–62]. However, even if information of the major metabolites is available from the 134 
literature, their analysis can be complicated due to the lack of reference standards, and therefore only 135 
tentative identifications may be possible using HRMS. 136 
 137 
Investigation of NPS in pooled urine 138 
The analysis of urine from intoxication cases or potential consumers seems, a priori, a suitable source 139 
of information for the monitoring of NPS [5,49]. However, it is not easy to obtain these samples, and 140 
the consent of the users or family members is required. The analysis of PU collected from places with 141 
higher probability of NPS consumption (e.g. discotheques, music festivals or nightlife areas) can give 142 
a more realistic picture of the NPS situation within a population. Besides, samples are anonymized 143 
and ethical issues are limited [63,64]. 144 
Table 1 summarizes the studies on PU analysis for NPS reported in the last five years. The vast majority 145 
of these studies applied the potential of LC-HRMS for qualitative identification of NPS using time-of-146 
flight (TOF) [48,65–67] or Orbitrap [68] mass analyzers. A few studies focused on a limited list of target 147 
compounds, which were quantified using low resolution mass analyzers (LC-MS/MS QqQ) [21].  148 
The selection of specific settings for the analysis of PU increases the degree of success in the detection 149 
of NPS. For this reason, 60% of the studies reported data from music festivals because of the higher 150 
probability of drugs or NPS consumption [48,65–67].  Samples were collected from urine containers 151 
of pissoirs, or from portable toilets, resulting in an anonymous mixture of urines from an 152 
undetermined numbers of contributors. It is remarkable that most studies collected samples from 153 
pissoirs, resulting in cleaner samples than those collected in portable toilets. The latter are 154 
contaminated with feces and disinfection chemicals, which may have an unknown effect on NPS 155 
stability. Furthermore, it must be taken into account that pissoirs are designed for men, and thus only 156 
represent a part of the setting. 157 
In these works, the most commonly detected NPS categories were synthetic cathinones and 158 
phenethylamines. It seems logical that mainly invigorating drugs were found since music festivals and 159 
nightlife locations are more prone to the intake of stimulant compounds. Paying attention to the 160 
individual NPS consumed, mephedrone [21,66,68] and ketamine [22,66–68] were the most reported 161 
drugs in PU analysis.   162 
 163 
Investigation of NPS in wastewater 164 
The application of WBE for the estimation of psychoactive substances consumption is mainly focused 165 
on ID [25], and has been scarcely applied to NPS. As mentioned in previous sections, the investigation 166 
of NPS in WW is very complicated due to several factors that make the full application of WBE to NPS 167 
still quite limited. The lack of information on excretion rates and metabolic pathways of NPS, and the 168 
very low concentrations in WW, are the main drawbacks. The majority of the published studies on 169 
NPS in WW only dealt with detections and concentrations, without producing either mass loads (i.e. 170 
concentrations multiplied by flow rates of WW) or normalized data to the population within the WW 171 
catchment area.  172 
Table 2 summarizes the main developments in the monitoring of NPS consumption through WW 173 
analysis. The vast majority of reported studies applied solid phase extraction (SPE) for the pre-174 
concentration of target compounds followed by LC-MS/MS (QqQ) analysis because of the enhanced 175 
sensitivity of this type of mass analyzers [23,24,49,54–57,69–77]. However, there are also studies 176 
using LC-HRMS [47–49,51,70,78–82].  Although back calculations to estimate the consumption of NPS 177 
by a population is complicated and for now unrealistic, the quantification of NPS (as in most of LC-178 
MS/MS methods) may give a better comprehension of the actual use when comparing with the mass 179 
loads found for conventional ID.   180 
Several studies focus the collection of samples on weekends, festivities or festivals, when higher 181 
concentrations of NPS in WW are expected [24,47,56]. In general, 24-hours composite samples are 182 
collected at the entrance of a wastewater treatment plant (WWTP).  183 
The NPS most found in WW are synthetic cathinones. Thus, 21 out of the 30 reviewed studies reported 184 
positive findings of at least one synthetic cathinone, of which methylone [23,48,49,54,55,77–79,83–185 
85] and mephedrone [23,24,49,54,73,75–77,79,81,84] were most often reported. Despite the fact 186 
that these compounds are currently illegal in many countries, they seem to be well-established in the 187 
drug market showing a recurrent detection in WW. Other NPS, such as synthetic cannabinoids, were 188 
scarcely detected [47,56,57,78,83], which could be related to the fact that synthetic cannabinoids are 189 
highly and quickly metabolized by humans [86,87], and therefore should be mostly found as major 190 
metabolites in WW. The particular case of synthetic opioids is of major concern because of the 191 
epidemic increase of opioids consumption over the last years, especially in the US [88], with alarming 192 
news stories in the ordinary press [89–91]. Recently, first detection of fentanyl and metabolites was 193 
reported by different studies in Europe and the US [72,77,92].  194 
Some compounds included in Tables 1 and 2 might not be considered as NPS, as it is very difficult to 195 
differentiate these compounds being used illicitly or legally. For example, hordenine is present in beer 196 
but some studies considered this substance as a ‘potential NPS’ [22,47,65,66]. Also, ketamine is used 197 
for certain applications as veterinary and medical drug, but is considered as a recreational substance 198 
by the EMCDDA. Besides, as stated above, this organism defines NPS as ‘newly misused’ substances, 199 
which embraces these cases of chemicals intended for other purposes than for which it is originally 200 
developed.  201 
The most of the scientific production about determination of NPS in WW is done over 2016 202 
[48,51,76,77,81,82,85], 2017 [23,47,69,79,80,83] and 2018 [49,70–74,92,93], with Europe being the 203 
most productive region [23,24,47,48,51,54–57,71,72,74–76,79–82,93], followed by Australia 204 
[49,70,77,78,84,85]. Asia [69,94], US [92] and Africa [73] have barely applied strategies for NPS 205 
monitoring through WW analysis. 206 
 207 
Future perspectives 208 
Monitoring NPS use through PU and WW analysis is a challenge due to several factors: 1) their rapid 209 
transience on the drug market creates a scenario with constantly moving analytical targets; 2) the lack 210 
of data on NPS metabolism and pharmacokinetics i.e. for the selection of unique biomarkers and 211 
information on excretion rates; 3) the lack of data on stability of potential biomakers in urine and 212 
sewage; 4) the generally very low concentrations, because of the high choice for consumers in number 213 
of compounds, the low dose of some NPS and low prevalence in use, plus the elevated dilution factor 214 
of WW i.e. dilution of urine and feces with water used in households, industry, etc.; 5) the high 215 
sensitivity and selectivity required in the analytical methods, as a consequence of the low analyte 216 
concentrations and the complexity of the sample matrix.  217 
Target quantitative methods based on LC-MS/MS QqQ, although limited by the target list of 218 
compounds, are useful because of the excellent sensitivity of this technique. However, LC-HRMS is the 219 
technique of choice for screening a large number of both NPS and metabolites.  Hence, the 220 
maintenance of comprehensive and updated databases is essential. Data from surveys, police 221 
seizures, forensic analyses, as well as from EWS, and the scientific literature are necessary. The 222 
database should be fed with information from analysis of the products potentially consumed (e.g. 223 
herbal blends, crystals, pilots, powder purchased online or in smart shops), where non-targeted 224 
analytical strategies may be necessary to identify non-expected or unknown compounds, in order to 225 
include substances that are actually sold on the market. Furthermore, the inclusion of metabolites in 226 
the database is pivotal for realistic studies, as it will allow focusing the analysis on those targets that 227 
are more likely present in urine and WW samples. 228 
Figure 2 illustrates the different steps and topics that should be considered to get a comprehensive 229 
overview on NPS use, including analysis of WW and PU as one of the key issues.  230 
As can be seen, the scenario around NPS use is rather complex. Lot of research is required in the next 231 
years to provide more information in different areas, with analytical chemistry playing a key role. Close 232 
collaboration is needed between different disciplines and actors that are relevant in the drugs 233 
scenario. This scenario includes not only collaboration between analytical chemists, but also 234 
toxicologists,  health professionals, as well as police forces, national governments, national focal 235 
points and organizations like EMCDDA and UNODC.  236 
Regarding WW analysis, more information is required for full application of WBE, such as excretion 237 
rates and stability of NPS in sewage, in order to obtain estimates of NPS consumed. Despite the 238 
limitations, data from screening WW (and PU) is highly valuable to understand the extent and actual 239 
use of NPS within certain populations, at least of those most widely consumed. In this context, HRMS 240 
screening of WW and PU collected from special settings (e.g. in festivals, near discotheques or 241 
nightclubs), where higher NPS consumption is expected, is a good strategy. The possibility to re-242 
evaluate HRMS data in a retrospective way, without the need of additional analysis, is worth to 243 
noticing as it allows re-examine data previously obtained searching for new/additional compounds 244 
not considered in the initial analysis. 245 
As illustrated in the workflow of Figure 2, different sources are needed to get a broad overview of NPS 246 
use. Data triangulation i.e. combining information obtained from PU and WW analysis with other 247 
sources, like survey data and forensic data, seems one of the best approaches nowadays to get a 248 
comprehensive insight on the NPS situation [49].  249 
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Table 1. Summary of recently reported studies on NPS determination in Pooled Urine samples. (4-chloro-α-PPP: 4'-chloro-α-pyrrolidinopropiophenone 4-542 
FA: 4-fluoroamphetamine; 5-APB: 5-(2-aminopropyl)benzofuran; α-PVP: α-pyrrolidinovalerophenone; BZP: 1-benzylpiperazine; M-234: 1-phenyl-2-543 
(pyrrolidin-1-yl)pentan-1-ol; M-264: hydroxy-4-((1-oxo-1-phenylpentan-2-yl)amino)butanal; TFMPP: trifluoromethylphenylpiperazine) 544 
Sampling area Type of sample Compounds 1 NPS positive findings 1 Analytical technique Reference 
United Kingdom 
(City of 
Westminster, 
London) 
Pooled urine 
Weekend sampling 
Pissoir (male urinal) 
1700 compounds (ID, NPS 
and metabolites) 
 
ketamine, hordenine, d-norpseudoephedrine, 
methylhexanamine, 4-methylmethcathinone, 
methopropamine and metabolites, 
methoxetamine and metabolites 
SPE, LLE 
LC-MS/MS 2 
Qualitative 
Archer, 2013 [22] 
Norway (Oslo) Pooled urine  
Sampling during  
festival 
Pissoir (male urinal) 
ID, NPS hordenine, 1-(2-methoxyphenylpiperazine), 
cathinone 
UHPLC-QTOF 
Qualitative 
Reid, 2014 [65] 
United Kingdom 
(Night Club in 
London) 
Pooled urine 
Weekend sampling 
Pissoir (male urinal) 
900 compounds (ID, 
pharmaceuticals, steroids, 
NPS and metabolites) 
mephedrone and metabolites, TFMPP and 
metabolites, 2-aminoindane 
 
SPE, LLE, shoot 
techniques 
LC- MS/MS 2 
Qualitative/Quantitative 
Archer, 2014 [21] 
United Kingdom 
(City of 
Westminster, 
London) 
Pooled urine 
Weekend sampling 
Pissoir (male urinal) 
ID, NPS mephedrone, methylhexaneamine, 
methiopropamine, pipradol, cathinone, 5-APB, 
4-methylethcathinone, TFMPP, 4-
methylbuphedrone, methcathinone, 
ethylmethcathinone, d-norpseudoephedrine, 
ketamine, 1,4-methoxyphenylpiperazine, 4-
fluoroephedrine 
 
SPE 
UHPLC-LTQ Orbitrap 
Qualitative 
Archer, 2014 [68] 
United Kingdom 
(City center and 
festival) and 
Belgium (festival)  
Pooled urine 
Weekend sampling 
in the city and during 
festivals 
Pissoir (male urinal) 
1500 compounds (ID, NPS 
and metabolites) 
MPA, methylone, ethylone, methedrone, 
mephedrone, dyhidromephedrone, 
normephedrone, 5-APB, ketamine, 
norketamine, hydroxynorketamine, 
dehydronorketamine, 4-FA, α-PVP, M-264 and 
M-234 (α-PVP metabolites), hordenine, 
methoxetamine 
 
UHPLC-QTOF 
Qualitative 
Kinyua, 2016 
[66] 
Sampling area Type of sample Compounds 1 NPS positive findings 1 Analytical technique Reference 
Norway (Festivals) Pooled urine 
Sampling during 
festivals 
Pissoir and portable 
toilets 
Suspect screening: 1000 
compounds (including ID, 
pharmaceuticals and 16 
NPS) 
Target: 51 compounds 
(including synthetic 
cathinones, 
phenethylamines, ketamine 
and phencyclidine-type 
sustances) 
methylphenidate, BZP SPE 
UHPLC-QTOF 
Qualitative 
Baz-Lomba, 
2016 [48] 
Denmark (Festival,  
Roskilde) 
Pooled urine 
Sampling during 
festival 
Portable toilets  
467 compounds (ID, NPS 
and metabolites) 
ketamine, methylphenidate SPE 
UHPLC-QTOF 
Qualitative 
Hoegberg, 2018 
[67] 
1 NPS metabolites highlighted in italic letters. 
2 No information available about the specified analytical technique used 
 545 
  546 
Table 2. Summary of recently reported studies on NPS determination in WW samples. (2C-B: 4-bromo-2,5-dimethoxyphenethylamine; 25H-NBOMe: 2,5-547 
dimethoxyphenethylamine; 3,4-DMMC: 3,4-dimethylmethylcathinone; 4-FMC: 4-fluoromehcathinone; 4-MEC: 4-methylcathinone; 4’MePHP: 4′ -methyl-α-548 
pyrrolidinohexanophenone; 5F-APINACA: N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide; α-PVP: α-pyrrolidinovalerophenone; MA-549 
2201: 1‐(5‐fluoropentyl)‐3‐(naphthalen‐1‐oyl)indole; BZP: 1-benzylpiperazine; CP47,497: 2-[(1S,3R)-3-Hydroxycyclohexyl]-5-(2-me thyl-2-octanyl) phenol; 550 
JWH-018: 1-Naphthyl (1-pentyl-1H- indol-3-yl) methanone; JWH-073: 1-naphthyl (1-butyl-1H-indol-3-yl) methanone; JWH-122: 4-Methyl-1-naphthyl) (1-551 
pentyl-1H-indol-3-yl) methanone; JWH-210: (4-Ethyl-1-naphthyl)(1- pentyl-1H-indol-3-yl) methanone; L-759,633: (6aR,10aR)-3-(1,1-Dimethylheptyl)-552 
6a,7,10,10a-tetrahydro-1-methoxy-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; mCPP: 1-(3-chlorophenyl)piperazine; MDA: 3,4-methylenedioxyamphetamine; 553 
MDEA: 3,4-methylenedioxyethylamphetamine; MDPV: methylenedioxypyrovalerone; MPA: methiopropamine; PMA: 4-methoxyamphetamine; PMMA: 4-554 
methoxymethamphetanime; TFMPP: trifluoromethylphenylpiperazine; U-47700: 3,4-Dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-555 
methylbenzamide; UR-144: (1‐pentylindol‐3‐yl)‐(2,2,3,3‐tetramet hylcyclopropyl)methanone) 556 
Sampling area Type of sample Compounds 1 Positive NPS findings 1 Analytical technique Reference 
Australia 
(Adelaide)  
24 h composite  MDMA, methcathinone, 
mephedrone, methylone, MDPV, 
BZP, TFMPP 
methcathinone, mephedrone, 
methylone, MDPV, BZP, TFMPP 
SPE 
UHPLC-Qtrap 
Quantitative 
Chen, 2013 [84] 
Norway (Oslo, 
Bergen, Harmar) 
72 h composite 
Weekend sampling 
14 NPS (synthetic cathinones, 
metabolites of synthetic 
cannabinoids and 
phenethylamines) 
d-norpseudoephedrine, 
pseudoephedrine, JWH-018 N-5-
hydroxypentyl 
SPE 
UHPLC-QqQ 
Quantitative 
Reid, 2014 [56] 
Belgium (Antwerp, 
Boechout, Ninove, 
Ruisbroek, Zele) 
and Switzerland 
(Zurich) 
24 h composite  methoxetamine, butylone, 
ethylone, methylone, MPA, 
PMMA, PMA 
methoxetamine, butylone, ethylone, 
methylone, PMMA 
SPE 
LC-QqQ 
Quantitative 
Kinyua, 2015 [55] 
South Korea 
(Busan, Ulsan, 
Changwon, 
Kimhae, Milyang) 
24 h composite  17 compounds (ID, ketamine, 
norketamine, mephedrone and 
methylone) 
None SPE 
UHPLC-Qtrap 
Quantitative 
Kim, 2015 [94] 
Greece (Santorini 
Island) 
Grab 10 NPS (synthetic cannabinoids, 
cathinones, piperazines and 
pyrrolidophenones) 
JWH-210, JWH-122, α-PVP, CP47,497 SPE 
UHPLC-QqQ 
Quantitative 
Borova, 2015 
[57] 
Sampling area Type of sample Compounds 1 Positive NPS findings 1 Analytical technique Reference 
Croatia (Zagreb, 
Vinkovci, Velika 
Gorika) 
24 h composite and 
grab  
25 NPS (mainly synthetic 
cathinones and other substituted 
phenylalkylamines) 
flephedrone, methylone, methedrone, 
mephedrone, ketamine, norketamine 
SPE  
LC-QqQ 
Quantitative 
Senta, 2015 [54] 
Italy (from 17 
cities) 
24 h composite  ketamine, mephedrone ketamine, mephedrone SPE 
UHPLC-QqQ 
Quantitative 
Castiglioni, 2015 
[75] 
Spain (Valencia) 24 h composite  Target: 42 compounds (21 
emerging psychoactive 
substances) 
Suspect screening: 2000 
compounds (pharmaceuticals, 
pesticides, mycotoxins and 
psychoactive substances) 
Target: ephedrine 
Suspect screening: ephedrine, 
ethylamphetamine, α-PVP,4'MePHP, 
ketamine, methylephedrone 
SPE 
UHPLC-QTOF MS/MS 
Quantitative/Qualitative 
Andrés-Costa, 
2016 [82] 
Italy (Milan, 
Bologna, Turin, 
Perugia) 
24 h composite  52 NPS (synthetic cannabinoids, 
synthetic cathinones, ketamine 
derivatives, phenethylamines and 
others) 
None SPE 
UHPLC-LTQ Orbitrap 
Qualitative 
González-
Mariño, 2016 [51] 
United Kingdom 
(Bath) 
24 h composite  56 compounds (ID, 
pharmaceuticals, mephedrone, 
ketamine, benzylpiperazine, 
ephedrine, pseudoephedrine and 
PMA) 
mephedrone, ketamine, 
benzylpiperazine, ephedrine  
SPE 
UHPLC-QqQ 
Quantitative 
Castrignano, 
2016 [76] 
Italy (Florence, 
Bologna, Turin, 
Perugia, Milan), 
Spain (Santiago de 
Compostela), 
Norway (Oslo) and 
United Kingdom 
(Southwest) 
24 h composite 
Weekend sampling 
18 synthetic cathinones mephedrone, N,N-dimethylcathinone, 
methcathinone, 4-FMC, 4-MEC, MDPV, 
ethylone 
SPE 
UHPLC-QqQ 
Quantitative 
González-
Mariño, 2016 [24] 
Australia (South 
East Queensland) 
24 h composite  methylone, mephredone methylone Direct injection 
LC-QqQ 
Quantitative 
Thai, 2016 [85] 
Sampling area Type of sample Compounds 1 Positive NPS findings 1 Analytical technique Reference 
Poland (Plaszow, 
Krakow) 
24 h composite  MDMA, mephedrone, 4-MEC, 
MDPV, mCPP 
mephedrone, 4-MEC SPE 
LC-QTOF 
Quantitative 
Styszko, 2016 
[81] 
Australia 
(Adelaide) 
24 h composite  21 compounds (ID and 10 NPS) methylone, methcathinone, MDPV, 
BZP, mephedrone, TFMPP, α-PVP 
SPE 
LC-QqQ 
Quantitative 
Tscharke, 2016 
[77] 
Norway (Oslo, 
Trondheim) 
24 h composite  51 compounds (ID, 
pharmaceuticals and 16 NPS) 
methylone, ketamine, methoxetamine  SPE (POCIS) 
UHPLC-QTOF 
Qualitative 
Baz-Lomba, 
2016 [48] 
The Netherlands 
(Amsterdam) 
24 h composite 
Sampling during 
festival 
2000 compounds (including ID, 
pharmaceuticals and NPS) 
PMMA, methylhexanamine, 4-
fluoroamphetamine, MDEA, mCPP, 2C-
B, fentanyl, L-759,633, ketamine, 
hordenine 
SPE 
UHPLC-QTOF 
UHPLC-LTQ Orbitrap 
Qualitative 
Causanilles, 
2017 [47] 
European cities 
(Zurich, 
Copenhagen, 
Oslo, Castellon, 
Milan, Brussels, 
Utrecht, Bristol) 
24 h composite  10 NPS (cathinones and 
phenethylamines) 
MDPV, mephedrone, methylone SPE 
UHPLC-QqQ 
Quantitative 
Bade, 2017 [23] 
Spain (Tarragona, 
Reus) 
24 h composite  10 compounds (ID, mephedrone, 
4-methylephedrine and MDPV) 
None SPE 
UHPLC-Exactive 
Orbitrap 
Quantitative 
Prosen, 2017 
[80] 
New Zeeland 
(Auckland) 
24 h composite  17 compounds (ID, methylone, 
ketamine norketamine, 
mephedrone, JWH-073 and JWH-
018) 
methylone, JWH-018 Direct injection, SPE 
LC-QqQ 
Quantitative 
Lai, 2017 [83] 
China (18 major 
cities) 
24 h composite  Mephedrone, MDPV, BZP, 
TFMPP, mCPP 
MDPV, BZP SPE 
UHPLC-QqQ 
Quantitative 
Gao, 2017 [69] 
Sampling area Type of sample Compounds 1 Positive NPS findings 1 Analytical technique Reference 
Spain (Tarragona) 24 h composite  12 synthetic cathinones and one 
metabolite 
flephredone, methylone, buphedrone, 
4-methylephedrine, butylone, 
mephedrone, pentedrone, 3,4-DMMC, 
α-PVP, MDPV 
SPE 
UHPLC-Exactive 
Orbitrap 
Quantitative 
Fontanals, 2017 
[79] 
South Australia 24 h composite  Qualitative: 346 compounds (ID, 
pharmaceuticals and NPS) 
Target: subset of these 
compounds 
α-PVP, MDPV SPE 
UHPLC-QqQ 
UHPLC-QTOF 
Quantitative/Qualitative 
Bade, 2018 [70] 
South Australia 24 h composite  187 NPS  Qualitative: α-PVP, ethylone, MDPV, 
mephedrone, methcathinone, 
methylone, BZP, TFMPP, pentylone, 
25H-NBOMe, MDA  
Quantitative: butylone, ethylone, α-
PVP, methcathinone, MDPV, 
pentylone, mephedrone 
 
SPE 
UHPLC-QqQ 
UHPLC-QTOF 
Quantitative/Qualitative 
Bade, 2018 [49] 
Spain (Santiago de 
Compostela) 
24 h composite  38 compounds (ID, 
pharmaceuticals, mephedrone, 
ketamine and mCPP) 
None SPE 
 UHPLC-QqQ 
Quantitative 
González-
Mariño, 2018 [71] 
Norway 
(Trondheim) 
24 h composite  8 compounds (THC, 3 metabolites 
of THC and 4 metabolites of 
synthetic cannabinoids) 
None  LLE 
UHPSFC-QqQ 
Quantitative 
González-
Mariño, 2018 [93] 
Croatia (Zagreb, 
Split) 
24 h composite  27 opioids and metabolites Detection of fentanyl, norfentanyl and 
sufentanil  
SPE 
UHPLC-QqQ 
Quantitative 
Krizman-Matasic, 
2018 [72] 
USA 
(Southwestern 
university campus) 
24 h composite  19 compounds (ID and 
metabolites, oxycodone, fentanyl, 
buprenorphine, methylphenidate, 
alprazolam) 
fentanyl, norfentanyl Isotope dilution (ID-LC-
MS/MS) 
Quantitative 
Gushgari, 2018 
[92] 
Sampling area Type of sample Compounds 1 Positive NPS findings 1 Analytical technique Reference 
South Africa 
(Johannesburg, 
Cape Town) 
24 h composite  18 compounds (ID, mephedrone, 
ephedrine, pseudoephedrine, 
norephedrine) 
mephedrone SPE 
UHPLC-QqQ 
Quantitative 
Archer, 2018 [73] 
Spain (Barcelona) 24 h composite  37 compounds (ID, 
pharmaceuticals, ephedrine, 
mephedrone, ketamine, 
methoxetamine, MDPV) 
None On-line SPE 
UHPLC-QqQ 
Quantitative 
López-García, 
2018 [74] 
Australia 24 h composite and 
grab  
187 NPS  Confirmed: MDA, AM-2201, UR-144, 4-
FMC, α-PVP, ethylone, methcathinone, 
methylone, pentedrone, methoxetamine 
Detected: 5F-APINACA, JWH-018, 
JWH-073, 4-MEC, butylone, 
mephedrone, pentylone, U-47700, 
methiopropamine 
SPE 
UHPLC-QTOF 
Qualitative 
Bade, 2019 [78] 
1 NPS metabolites highlighted in italic letters. 
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Figure captions 559 
Figure 1: Number and categories of new psychoactive substances notified to the EU Early Warning 560 
System for the first time within 2005-2017 (reproduced with authorization from the 561 
European Drug Report 2018 of the EMCDDA [3]) 562 
 563 
Figure 2: Sources of information, steps and topics required to build a comprehensive database for 564 
monitoring NPS use 565 
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